Cargando…
The Mechanism of Rac1 in Regulating HCC Cell Glycolysis Which Provides Underlying Therapeutic Target for HCC Therapy
AIM: To explore the role of Rac1 on sorafenib resistance in hepatocellular carcinoma. METHODS: CCK-8, wound healing assay, Transwell, and cell cycle assay were used to detect the tumor cells development. Cell viability was assessed by MTT. The glycolytic pathway was revealed by cellular metabolism a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279021/ https://www.ncbi.nlm.nih.gov/pubmed/35847360 http://dx.doi.org/10.1155/2022/7319641 |
_version_ | 1784746299645493248 |
---|---|
author | Ren, Yin-Xiang Li, Xiao-Bin Liu, Wei Yang, Xu-Guang Liu, Xin Luo, Yu |
author_facet | Ren, Yin-Xiang Li, Xiao-Bin Liu, Wei Yang, Xu-Guang Liu, Xin Luo, Yu |
author_sort | Ren, Yin-Xiang |
collection | PubMed |
description | AIM: To explore the role of Rac1 on sorafenib resistance in hepatocellular carcinoma. METHODS: CCK-8, wound healing assay, Transwell, and cell cycle assay were used to detect the tumor cells development. Cell viability was assessed by MTT. The glycolytic pathway was revealed by cellular metabolism assays. RESULT: We recovered that Rac1 upregulation was related to HCC patients' poorer prognosis. Forced expression of Rac1 promoted cell development and sorafenib chemoresistance in HCC cells. Rac1 inhibitor EHop-016 and sorafenib combination markedly prevented cell viability, G2/M phase cycle arrest, and apoptosis than single therapy. Furthermore, combination therapy decreased glycolysis in HCC cells. In vivo, the tumor growth was significantly prevented by combination therapy single therapy. CONCLUSION: Our research declares that Rac1 inhibition could block sorafenib resistance in HCC by decreasing glycolysis, which would provide an underlying target for HCC therapy. |
format | Online Article Text |
id | pubmed-9279021 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-92790212022-07-14 The Mechanism of Rac1 in Regulating HCC Cell Glycolysis Which Provides Underlying Therapeutic Target for HCC Therapy Ren, Yin-Xiang Li, Xiao-Bin Liu, Wei Yang, Xu-Guang Liu, Xin Luo, Yu J Oncol Research Article AIM: To explore the role of Rac1 on sorafenib resistance in hepatocellular carcinoma. METHODS: CCK-8, wound healing assay, Transwell, and cell cycle assay were used to detect the tumor cells development. Cell viability was assessed by MTT. The glycolytic pathway was revealed by cellular metabolism assays. RESULT: We recovered that Rac1 upregulation was related to HCC patients' poorer prognosis. Forced expression of Rac1 promoted cell development and sorafenib chemoresistance in HCC cells. Rac1 inhibitor EHop-016 and sorafenib combination markedly prevented cell viability, G2/M phase cycle arrest, and apoptosis than single therapy. Furthermore, combination therapy decreased glycolysis in HCC cells. In vivo, the tumor growth was significantly prevented by combination therapy single therapy. CONCLUSION: Our research declares that Rac1 inhibition could block sorafenib resistance in HCC by decreasing glycolysis, which would provide an underlying target for HCC therapy. Hindawi 2022-07-06 /pmc/articles/PMC9279021/ /pubmed/35847360 http://dx.doi.org/10.1155/2022/7319641 Text en Copyright © 2022 Yin-Xiang Ren et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ren, Yin-Xiang Li, Xiao-Bin Liu, Wei Yang, Xu-Guang Liu, Xin Luo, Yu The Mechanism of Rac1 in Regulating HCC Cell Glycolysis Which Provides Underlying Therapeutic Target for HCC Therapy |
title | The Mechanism of Rac1 in Regulating HCC Cell Glycolysis Which Provides Underlying Therapeutic Target for HCC Therapy |
title_full | The Mechanism of Rac1 in Regulating HCC Cell Glycolysis Which Provides Underlying Therapeutic Target for HCC Therapy |
title_fullStr | The Mechanism of Rac1 in Regulating HCC Cell Glycolysis Which Provides Underlying Therapeutic Target for HCC Therapy |
title_full_unstemmed | The Mechanism of Rac1 in Regulating HCC Cell Glycolysis Which Provides Underlying Therapeutic Target for HCC Therapy |
title_short | The Mechanism of Rac1 in Regulating HCC Cell Glycolysis Which Provides Underlying Therapeutic Target for HCC Therapy |
title_sort | mechanism of rac1 in regulating hcc cell glycolysis which provides underlying therapeutic target for hcc therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279021/ https://www.ncbi.nlm.nih.gov/pubmed/35847360 http://dx.doi.org/10.1155/2022/7319641 |
work_keys_str_mv | AT renyinxiang themechanismofrac1inregulatinghcccellglycolysiswhichprovidesunderlyingtherapeutictargetforhcctherapy AT lixiaobin themechanismofrac1inregulatinghcccellglycolysiswhichprovidesunderlyingtherapeutictargetforhcctherapy AT liuwei themechanismofrac1inregulatinghcccellglycolysiswhichprovidesunderlyingtherapeutictargetforhcctherapy AT yangxuguang themechanismofrac1inregulatinghcccellglycolysiswhichprovidesunderlyingtherapeutictargetforhcctherapy AT liuxin themechanismofrac1inregulatinghcccellglycolysiswhichprovidesunderlyingtherapeutictargetforhcctherapy AT luoyu themechanismofrac1inregulatinghcccellglycolysiswhichprovidesunderlyingtherapeutictargetforhcctherapy AT renyinxiang mechanismofrac1inregulatinghcccellglycolysiswhichprovidesunderlyingtherapeutictargetforhcctherapy AT lixiaobin mechanismofrac1inregulatinghcccellglycolysiswhichprovidesunderlyingtherapeutictargetforhcctherapy AT liuwei mechanismofrac1inregulatinghcccellglycolysiswhichprovidesunderlyingtherapeutictargetforhcctherapy AT yangxuguang mechanismofrac1inregulatinghcccellglycolysiswhichprovidesunderlyingtherapeutictargetforhcctherapy AT liuxin mechanismofrac1inregulatinghcccellglycolysiswhichprovidesunderlyingtherapeutictargetforhcctherapy AT luoyu mechanismofrac1inregulatinghcccellglycolysiswhichprovidesunderlyingtherapeutictargetforhcctherapy |